

FORM PTO-1449

U.S. Dept. of Commerce

Atty Docket No.

Serial No.

P1071P2C2

09/723,185

Applicant

Chen et al.

Filing Date

27 Nov 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

JAN 11 2001

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
DR	*	1	4,411,890	25.10.83	Momany, Frank A.		
	*	2	4,876,242	24.10.89	Applebaum, J. et al.		
	*	3	4,988,675	29.01.91	Froesch et al.		
	*	4	5,068,224	26.11.91	Fryklund et al.		
	*	5	5,077,276	31.12.91	Ballard, F. et al.		
	*	6	5,093,317	03.03.92	Lewis et al.		
	*	7	5,106,832	21.04.92	Froesch et al.		
	*	8	5,126,324	30.06.92	Clark et al.		
	*	9	5,164,370	17.11.92	Ballard, F. et al.		
	*	10	5,187,151	16.02.93	Clark et al.		
	*	11	5,202,119	13.04.93	Clark et al.		
	*	12	5,206,235	27.04.93	Fisher, M. H. et al.		
	*	13	5,210,017	11.05.93	Carlsson, L. et al.		
	*	14	5,223,409	29.06.93	Ladner et al.		
	*	15	5,273,961	28.12.93	Clark		
	*	16	5,374,620	20.12.94	Clark et al.		
	*	17	5,466,670	14.11.95	Dunger, D.B. et al.		
	*	18	5,470,828	28.11.95	Ballard et al.		
	*	19	5,534,617	09.07.96	Cunningham et al.		
	*	20	5,569,648	29.10.96	Lewis, M. et al.		
	*	21	5,593,844	14.01.97	Carlsson, L. et al.		
	*	22	5,597,797	28.01.97	Clark, R.		
	*	23	5,622,932	22.04.97	DiMarchi et al.		
	*	24	5,652,214	29.07.97	Lewis et al.		
	*	25	5,703,045	30.12.97	Lewis et al.		
DR	*	26	5,714,460	03.02.98	Gluckman et al.		
	*	27	5,776,897	07.07.98	Lewis et al.		

RECEIVED
FEB 22 2001
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
DR	*	28	128,733	19.12.84	EPO		
	*	29	135,094	27.03.85	EPO		
	*	30	230,869	05.08.87	EPO		
	*	31	288,451	26.10.88	EPO		
	*	32	294,021	07.12.88	EPO		
DR	*	33	369,943	23.05.90	EPO		

Examiner


David R. ...

Date Considered

1/24/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1071P2C2

Serial No.

09/723,185

Applicant

Chen et al.

Filing Date

27 Nov 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
AR	*	34	375,438	27.06.90	EPO			
	*	35	379,338	25.07.90	EPO			
	*	36	681,842	15.11.95	EPO			
	*	37	742,228	13.11.96	EPO			
	*	38	965,596	22.12.99	EPO			
	*	39	WO 00/23469	27.04.00	PCT			
	*	40	WO 89/05822	29.06.89	PCT			
	*	41	WO 89/08667	21.09.89	PCT			
	*	42	WO 89/09268	05.10.89	PCT			
	*	43	WO 89/09792	19.10.89	PCT			
	*	44	WO 91/03253	21.03.91	PCT			
	*	45	WO 92/11865	23.07.92	PCT			
	*	46	WO 92/15679	17.09.92	PCT			
	*	47	WO 93/08826	13.05.93	PCT			
	*	48	WO 93/20836	28.10.93	PCT			
	*	49	WO 93/23071	25.11.93	PCT			
	*	50	WO 93/25219	23.12.93	PCT			
	*	51	WO 94/04569	03.03.94	PCT			
	*	52	WO 94/16722	04.08.94	PCT			
	*	53	WO 94/16723	04.08.94	PCT			
	*	54	WO 95/07697	23.03.95	PCT			
	*	55	WO 95/17422	29.06.95	PCT			
	*	56	WO 95/17423	29.06.95	PCT			
	*	57	WO 96/01124	18.01.96	PCT			
	*	58	WO 96/15148	23.05.96	PCT			
	*	59	WO 96/33216	24.10.96	PCT			
	*	60	WO 96/37514	28.11.96	PCT			
	*	61	WO 96/40189	19.12.96	PCT			
	*	62	WO 96/40750	19.12.96	PCT			
	*	63	WO 97/37010	09.10.97	PCT			
	*	64	WO 97/39032	23.10.97	PCT			
	*	65	WO 98/20036	14.05.98	PCT			
	*	66	WO 98/45427	15.10.98	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AR	* 67	Alberts et al. <u>Molecular Biology of the Cell</u> , 3RD edition, New York:Garland Publishing, Inc. pps. 119 (1994)
AR	* 68	Bach and Rechler, "Insulin-like Growth Factor Binding Proteins" <u>Diabetes Reviews</u> 3:38-61 (1995)

Examiner

A. J. Rono

Date Considered

1/24/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1071P2C2	Serial No. 09/723,185
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Chen et al.	
				Filing Date 27 Nov 2000	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
PR	* 69	Ballard et al., "Does IGF-I Ever Act Through the Insulin Receptor?" <u>The Insulin-like Growth Factors and Their Regulatory Proteins</u> , Baxter, eds., Amsterdam: Elsevier pps. 131-138 (1994)			
	* 70	Bar et al., "Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I" <u>Endocrinology</u> 127(6):3243-3245 (1990)			
	* 71	Barinaga, M., "Neurotrophic factors enter the clinic [news]" <u>Science</u> 264:772-774 (1994)			
	* 72	Bass et al., "Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties" <u>Proteins: Structure, Function, and Genetics</u> 8(4):309-314 (1990)			
	* 73	Baxter & Martin, "Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins" <u>Biochem. & Biophys. Res. Comm.</u> 147(1):408-415 (1987)			
	* 74	Baxter et al., "Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3" <u>Journal of Biological Chemistry</u> 267(1):60-65 (Jan 5, 1992)			
	* 75	Baxter, "Physiological Roles of IGF Binding Proteins" <u>Modern Concepts of Insulin-like Growth Factors</u> , Spencer, eds., Elsevier, New York pps. 371-380 (1991)			
	* 76	Baxter, "The somatomedins: insulin-like growth factors" <u>Advances in Clinical Chemistry</u> 25:49-115 (1986)			
	* 77	Baxter, R., "The Insulin-Like Growth Factors and Their Binding Proteins" <u>Comp. Biochem. Physiol.</u> 91B(2):229-235 (1988)			
	* 78	Bayne et al., "Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor" <u>Journal of Biological Chemistry</u> 263:6233-6239 (1988)			
	* 79	Bayne et al., "The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor" <u>Journal of Biological Chemistry</u> 264(19):11004-11008 (Jul 5, 1989)			
	* 80	Bayne et al., "The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor" <u>Journal of Biological Chemistry</u> 265(26):15648-15652 (Sep 15, 1990)			
	* 81	Binkert et al., "Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)" <u>EMBO Journal</u> 8:2497-2502 (1989)			
	* 82	Binoux, M., "Données recentes sur les somatomedines (Insulin-like growth factors)" <u>Annales d'Endocrinologie</u> 41:157-192 (1980)			
	* 83	Bondy, C., "Clinical uses of insulin-like growth factor I" <u>Annals of Internal Medicine</u> 120:593-601 (1994)			
	* 84	Bowers, C. Y., "GH Releasing Peptides - Structure and Kinetics" <u>J. Pediatr. Endocrinology</u> 6(1):21-31 (1993)			
	* 85	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions" <u>Science</u> 247:1306-1310 (1990)			
	* 86	Brandt et al., "Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide" <u>American Journal of Physiology</u> 269(1 Pt 2):H326-H331 (Jul 1995)			
	* 87	Brewer et al., "Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein" <u>Biochem. & Biophys. Res. Comm.</u> 152(3):1289-1297 (1988)			
PR	* 88	Brinkman et al., "Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)" <u>The EMBO J.</u> 7:2417-2423 (1988)			
Examiner <i>James Ramez</i>				Date Considered 1/24/3	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1071P2C2

Serial No.

09/723,185

Applicant

Chen et al.

Filing Date

27 Nov 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AR	* 89	Carlsson et al., "Growth Hormone and Growth in Diabetic Rats: Effects of Insulin and Insulin-Like Growth Factor-I Infusions" <u>J. Endocrinol.</u> 122:661-670 (1989)
	* 90	Cascieri et al., "Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins" <u>Advances in Experimental Medicine & Biology</u> 343:33-40 (1993)
	* 91	Cascieri et al., "Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor" <u>Biochemistry</u> 27(9):3229-3233 (May 3, 1988)
	* 92	Cascieri et al., "Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors" <u>Journal of Biological Chemistry</u> 264:2199-2202 (1989)
	* 93	Charlton et al., "Growth hormone-deficient dwarfism in the rat: a new mutation" <u>J. of Endocrinology</u> 119:51-58 (1988)
	* 94	Cheetham et al., "The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependent Diabetes Mellitus" <u>Clin. Endocrinol.</u> 40:515-522 (1994)
	* 95	Cheetham et al., "The Effects of Recombinant Insulin-like Growth Factor I Administration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type 1 (Insulin-dependent) Diabetes Mellitus" <u>Diabetologia</u> 36:678-681 (1993)
	* 96	Chen et al., "Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation" <u>US Endocrine Meeting</u> (Abstract 1596) pps. 449 (1993)
	* 97	Clark et al., "Growth-Responses to Patterned GH Delivery" <u>Endocrine</u> 3:717-723 (1995)
	* 98	Clark et al., "Insulin-Like Growth Factor-I and Growth Hormone (GH) Have Distinct and Overlapping anabolic Effects in GH-Deficient Rats" <u>Endocrine</u> 3:297-304 (1995)
	* 99	Clemmons and Van Wyk, "Somatomedin: physiological control and effects on cell proliferation" <u>Handbook Exp. Pharmacol.</u> 57:161-208 (1981)
	*100	Clemmons et al., "Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs" <u>Endocrinology</u> 131(2):890-895 (Aug 1992)
	*101	Clemmons et al., "Discrete Alterations of the Insulin-like Growth Factor I Molecule Which Alter Its Affinity for Insulin-like Growth Factor-binding Proteins Result in Changes in Bioactivity" <u>Journal of Biological Chemistry</u> 265(21):12210-12216 (1990)
	*102	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands" <u>Proc. Natl. Acad. Sci. USA</u> 87(16):6378-6382 (1990)
	*103	Devlin et al., "Random peptide libraries: a source of specific protein binding molecules" <u>Science</u> 249:404-406 (1990)
	*104	Dubaquie et al., "Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor I (IGF-I) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3" <u>Biochemistry</u> 38(20):6386-6396 (1999)
	*105	Duerr et al., "Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure" <u>J. Clin. Invest.</u> 95:619-627 (1995)
	*106	Elahi et al., "Hemodynamic and metabolic responses to human insulin-like growth factor I (IGF-I) in men" <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, EM, ed., New York:Elsevier Science Publ. Co. pps. 219-224 (1991)
	*107	Fielder et al., "Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats" <u>Endocrinology</u> 137:1913-1920 (1996)
AR	*108	Franklin et al., "Insulin-Like Growth Factor I Preserves Renal Function Postoperatively" <u>Am. J. Physiol.</u> 272:F257-F259 (1997)

Examiner


Dariusz Roman

Date Considered

1/24/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1071P2C2

Serial No.

09/723,185

Applicant

Chen et al.

Filing Date

27 Nov 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

PR	*109	Froesch et al., "Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I" <u>Horm. Res.</u> 42:66-71 (1994)
	*110	Furnsinn et al., "Insulin-Like Growth Factor-I Inhibits Insulin and Amylin Secretion in Conscious Rats" <u>Endocrinology</u> 135(5):2144-2149 (1994)
	*111	Geysen et al., "A priori delineation of a peptide which mimics a discontinuous antigenic determinant" <u>Molecular Immunology</u> 23(7):709-715 (1986)
	*112	Ghazzi et al., "Cardiac and glycemic benefits of troglitazone treatment in NIDDM" <u>Diabetes</u> 46:433-439 (1997)
	*113	Giebel et al., "Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities" <u>Biochemistry</u> 34:15430-15435 (1995)
	*114	Guler et al., "Effects of Insulin-like Growth Factor I in Man" <u>Acta Paediatr. Scand.</u> 367:52-54 (Suppl. 1990)
	*115	Guler et al., "Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects" <u>Proc. Natl. Acad. Sci. USA</u> 86:2868-2872 (April 1989)
	*116	Guler et al., "Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man" <u>Acta Endocrinologica</u> 121:101-106 (1989)
	*117	Guler et al., "Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats" <u>Proc. Natl. Acad. Sci. USA</u> 85:4889-4893 (1988)
	*118	Guler et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults" <u>New England J. of Medicine</u> 317(3):137-140 (1987)
	*119	Hammerman and Miller, "The growth hormone insulin-like factor axis in kidney revisited" <u>Am. J. Physiol.</u> 265:F1-F14 (1993)
	*120	Hammerman and Miller, "Therapeutic use of growth factors in renal failure" <u>J. Am. Soc. Nephrol.</u> 5:1-11 (1994)
	*121	Hampton et al., "Purification and Characterization of an Insulin-like Growth Factor II Variant from Human Plasma" <u>Journal of Biological Chemistry</u> 264(32):19155-19160 (November 15, 1989)
	*122	Hartman et al., "A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans" <u>J. Clin. Invest.</u> 91:2453-2462 (1993)
	*123	Hasegawa et al., "The free form of insulin-like growth factor I increases in circulation during normal human pregnancy" <u>J. Clin. Endocrinol. Metabol.</u> 80:3284-3286 (1995)
	*124	Heding et al., "Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3" <u>Journal of Biological Chemistry</u> 271(24):13948-13952 (Jun 14, 1996)
	*125	Hirschberg et al., "Effects of insulin-like growth factor I on renal function in normal men" <u>Kidney International</u> 43:387-397 (1993)
	*126	Hizuka et al., "Measurement of free form of insulin-like growth factor I in human plasma" <u>Growth Regulation</u> 1:51-55 (1991)
	*127	Humbel, "Insulin-like growth factors I and II" <u>European Journal of Biochemistry</u> 190:445-462 (1990)
PR	*128	Jabri et al., "Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients" <u>Diabetes</u> 43:369-374 (1994)

Examiner

Daniel Rame

Date Considered

1/24/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1071P2C2

Serial No.

09/723,185

Applicant

Chen et al.

Filing Date

27 Nov 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AR	*129	Johnson et al., "Underexpression of β cell high K_m glucose transporters in noninsulin-dependent diabetes" <u>Science</u> 250:546-549 (1990)
	*130	Jones et al., "Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions" <u>Endocrine Reviews</u> 16(1):3-34 (1995)
	*131	Juul et al., "Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty" <u>Clin. Endocrinology</u> 44:515-523 (1996)
	*132	Kay et al., "An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets" <u>Gene</u> 128:59-65 (1993)
	*133	Kerr et al., "Effect of Insulin-like Growth Factor 1 on the Responses to and Recognition of Hypoglycemia" <u>Diabetes: American Diabetes Association (ADA), San Antonio, Texas, June 20-23, 1992</u> (abstract #225), 52nd Annual Meeting edition 41(supp 1):60A (Jun 1992)
	*134	Kerr et al., "Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans" <u>J. Clin. Invest.</u> 91:141-147 (1993)
	*135	Kletzien et al., "Enhancement of adipocyte differentiation by an insulin-sensitizing agent" <u>Molecular Pharmacology</u> 41(2):393-398 (Feb 1992)
	*136	Kupfer et al., "Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously" <u>J. Clin. Invest.</u> 91:391-396 (1993)
	*137	Kuzuya et al., "Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes" <u>Diabetes</u> 42:696-705 (1993)
	*138	Lassalle et al., "ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines" <u>Journal of Biological Chemistry</u> 271:20458-20464 (1996)
	*139	Leahy et al., "Insulin-Like Growth Factor-I at Physiological Concentrations is a Potent Inhibitor of Insulin Secretion" <u>Endocrinology</u> 126(3):1593-1598 (1990)
	*140	Lee et al., "Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests an IGF Binding Domain Different from Those of the IGF-I and IGF-II Receptors" <u>Mol. Endocrinol.</u> 2(5):404-411 (1988)
	*141	Lee et al., "Regulation and function of insulin-like growth factor-binding protein-1" <u>Proc. Soc. Exp. Biol. & Med.</u> 204:4-29 (1993)
	*142	Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression" <u>Nature</u> 330:537-543 (1987)
	*143	Lewitt and Baxter, "Insulin-like growth factor-binding protein-1: a role in glucose counterregulation?" <u>Mol. Cell. Endocrinology</u> 79(1-3):C147-C152 (1991)
	*144	Lewitt et al., "Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3" <u>Endocrinology</u> 133:1797-1802 (1993)
	*145	Lewitt et al., "Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels" <u>Endocrinology</u> 129(4):2254-2256 (1991)
	*146	Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia" <u>US Endocrine Meeting</u> (Abstract 1664) pps. 466 (1993)
	*147	Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome" <u>J. Clin. Endocrinol. and Metab.</u> 78(2):404-410 (1994)
AR	*148	Lieberman et al., "Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans" <u>J. Clin. Endocrinol. and Metab.</u> 75(1):30-36 (1992)

Examiner

James Rame

Date Considered

1/24/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

JAN 11 2001

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1071P2C2

Serial No.

09/723,185

Applicant

Chen et al.

Filing Date

27 Nov 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AR	*149	Livnah et al., "Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å" <u>Science</u> 273(5274):464-471 (Jul 26, 1996)
	*150	Loddick et al., "Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke" <u>Proc. Natl. Acad. Sci. USA</u> 95(4):1894-1898 (Feb 17, 1998)
	*151	Lowman et al., "Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions" <u>Biochemistry</u> 37(25):8870-8878 (1998)
	*152	Lowman et al., "Peptides that displace IGFs from their BPS as potential novel treatment modalities of growth disorders-basic aspects" (Abstract presented at the Intl. Pediatric Nephrology Assn.'s 6th Symposium on Growth and Development in Children with Chronic Renal Failure held in NY on March 11-13, 1999)
	*153	Lowman, H., "Bacteriophage display and discovery of peptide leads for drug development" <u>Annual Review of Biophysics and Biomolecular Structure</u> 26:401-424 (1997)
	*154	Lowman, H., "Phage display of peptide libraries on protein scaffolds" <u>Methods in Molecular Biology</u> , Chapter 24, 87:249-264 (1998)
	*155	Maack et al., "Physiological Role of Silent Receptors of Atrial Natriuretic Factor" <u>Science</u> 238:675-678 (Oct 30, 1987)
	*156	Martin & Baxter, "Insulin-like Growth Factor-binding Protein from Human Plasma. Purification and Characterization" <u>Journal of Biological Chemistry</u> 261(19):8754-8760 (1986)
	*157	McLafferty et al., "M13 bacteriophage displaying disulfide-constrained microproteins" <u>Gene</u> 128:29-36 (1993)
	*158	Miller et al., "Effects of IGF-I on renal function in end-stage chronic renal failure" <u>Kidney International</u> 46:201-207 (1994)
	*159	Morrow et al., "Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance" <u>Diabetes-53rd Annual Meeting, June 12-15, 1993</u> (abstract No. 269) 42:83A (Suppl. 1 1993)
	*160	O'Neill et al., "Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library" <u>Proteins: Structure, Function, and Genetics</u> 14:509-515 (1992)
	*161	O'Shea and Layish, "Growth hormone and the kidney: a case presentation and review of the literature" <u>J. Am. Soc. Nephrol.</u> 3:157-161 (1992)
	*162	O'Shea et al., "Effects of IGF-I on renal function in patients with chronic renal failure" <u>Am. J. Physiol.</u> 264:F917-F922 (1993)
	*163	Oh et al., "Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs" <u>Endocrinology</u> 132:1337-1344 (1993)
	*164	Oh et al., "Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II" <u>Journal of Biological Chemistry</u> 271:30322-30325 (1996)
	*165	Oldenburg et al., "Peptide ligands for a sugar-binding protein isolated from a random peptide library" <u>Proc. Natl. Acad. Sci.</u> 89:5393-5397 (1992)
	*166	Peterkofsky et al., "Elevated Activity of Low Molecular Weight Insulin-Like Growth Factor-Binding Proteins in Sera of Vitamin C-Deficient and Fasted Guinea Pigs" <u>Endocrinology</u> 128(4):1769-1779 (1991)
	*167	Phelan et al., "A General Method for Constraining Short Peptides to an α -Helical Conformation" <u>J. Am. Chem. Soc.</u> 119(3):455-460 (Jan 22, 1997)
AR	*168	Quin et al., "Acute Response to Recombinant Insulin-like Growth Factor I in a Patient with Mendenhall's Syndrome" <u>New England J. of Medicine</u> 323:1425-1426 (1990)

Examiner


Daniel R. Rowe

Date Considered

1/24/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1071P2C2

Serial No.

09/723,185

Applicant

Chen et al.

Filing Date

27 Nov 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AR	*169	Rinderknecht and Humbel, "Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II" <u>Proc. Natl. Acad. Sci USA</u> 73(7):2365-2369 (1976)
	*170	Rinderknecht and Humbel, "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin" <u>Journal of Biological Chemistry</u> 253(8):2769-2776 (1978)
	*171	Ross et al., "The Role of Insulin, Growth Hormone and IGF-I as Anabolic Agents in the Critically Ill" <u>Intensive Care Med.</u> 19(2):S54-S57 (Suppl. 1993)
	*172	Rudinger, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence" <u>Peptide Hormones</u> , J.A. Parsons, Baltimore:University Park Press pps. 1-7 (1976)
	*173	Saad et al., "Low-doses of Insulin-like Growth Factor-I Improve Insulin Sensitivity" <u>Diabetologia</u> (Abstract 152) 37:A40 (Suppl. 1 1994)
	*174	Schalch et al., "Short-Term Effects of Recombinant Human Insulin-Like Growth Factor I on Metabolic Control of Patients with Type II Diabetes Mellitus", <u>J. of Clinical Endocrinology & Metabolism</u> 77(6):1563-1568 (1993)
	*175	Schalch et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I (rhIGF-I) in type II diabetes mellitus" <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, ed., New York:Elsevier Science Publ. Co. pps. 705-713 (1991)
	*176	Schoen et al., "Growth Hormone Secretagogues" <u>Annual Reports in Medicinal Chemistry: Section IV-Immunology, Endocrinology & Metabolic Diseases</u> , William K. Hagmann, Chapter 19, Vol. 28:177-186 (1993)
	*177	Schoenle et al., "Recombinant human insulin-like growth factor I(rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance" <u>Diabetologia</u> 34:675-679 (1991)
	*178	Scott and Smith, "Searching for peptide ligands with an epitope library" <u>Science</u> 249:386-390 (1990)
	*179	Sherwin et al., "Metabolic Effects of Insulin-like Growth Factor I in Normal Humans" <u>Horm. Res.</u> 41:97-101 (Suppl. 2 1994)
	*180	Skottner et al., "Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I" <u>Endocrinology</u> 124(5):2519-2526 (1989)
	*181	Smith, "Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface" <u>Science</u> 228(4705):1315-1317 (1985)
	*182	Stern et al., "Insulin resistance and pancreatic insulin release in the genetically obese Zucker rat" <u>Proc. Soc. Exp. Biol. Med.</u> 139:66-69 (1972)
	*183	Suikkari et al., "Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein" <u>J. Clin. Endocrinology Metabol.</u> 66:266-272 (1988)
	*184	Swissheim et al., "Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid" <u>Proc. Natl. Acad. Sci.</u> 92:4472-4476 (1995)
	*185	Takano et al., "Effects of sc Administration of Recombinant Human Insulin-like Growth Factor I (IGF-I) on Normal Human Subjects" <u>Endocrinol. Japan</u> 37(2):309-317 (1990)
	*186	Tanner et al., "Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency" <u>Acta Endocrinologica</u> 84:681-696 (1977)
	*187	Underwood et al., "Regulation of somatomedin-c/insulin-like growth factor I by nutrients" <u>Hormone Res.</u> 24:166-176 (1986)
AR	*188	Usala et al., "Brief report: treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes" <u>New England J. of Medicine</u> 327(12):853-857 (1992)

Examiner

Daniel Rome

Date Considered

1/24/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

09/723.185

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|------|--|
| *189 | Uthne et al., "Effects of human somatomedin preparations on membrane transport and protein synthesis in the isolated rat diaphragm" <u>J. Clin. Endocrinol. Metab.</u> 39(3):548-554 (1974) |
| *190 | Van Wyk et al., "The somatomedins: a family of insulinlike hormones under growth hormone control" <u>Recent Prog. Horm. Res.</u> 30:259-318 (1974) |
| *191 | Vlachopapadopoulou et al., "Metabolic and Clinical Response to Recombinant Human Insulin-like Growth Factor I in Myotonic Dystrophy - A Clinical Research Center Study" <u>J. Clin. Endo. Metab.</u> 80(12):3715-3723 (1995) |
| *192 | Wells and Lowman, "Rapid Evolution of Peptide and Protein Binding Properties in Vitro" <u>Curr. Opin. Struct. Biol.</u> 2:597-604 (1992) |
| *193 | Wells, J. A., "Additivity of Mutational Effects in Proteins" <u>Biochemistry</u> 29(37):8509-8517 (Sep 18, 1990) |
| *194 | Wilton et al., "Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome)" <u>Acta Paediatr Suppl</u> 383:137-142 (1992) |
| *195 | Wood et al., "Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein" <u>Molecular Endocrinology</u> 2:1176-1185 (1988) |
| *196 | Wood et al., "Crystal structure analysis of deamino-oxytocin: conformational flexibility and receptor binding" <u>Science</u> 232:633-636 (1986) |
| *197 | Wrighton et al., "Small peptides as potent mimetics of the protein hormone erythropoietin" <u>Science</u> 273:458-463 (1996) |
| *198 | Yamauchi et al., "Purification and molecular cloning of prostacyclin-stimulating factor from serum-free, conditioned medium of human diploid fibroblast cells" <u>Biochemical Journal</u> 303(Part 2):591-598 (1994) |
| *199 | Zenobi et al., "Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion" <u>J. Clin. Invest.</u> 89:1908-1913 (1992) |
| *200 | Zenobi et al., "Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus" <u>J. Clin. Invest.</u> 90:2234-2241 (1992) |

Harold Rowe

 $1/24/3$

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.